Background:CD79b is a B-cell-specific antigen that is crucial to the B-cell receptor and is considered a key target for treatment in aggressive B-cell lymphomas.Methods:While immunohistochemical studies have shown widespread expression of CD79b in mature B-cell-derived lymphomas, flow cytometry allows for precise measurement and differentiation between surface and intracellular localization.Results:In our comparative analysis, we discovered that CD79b expression percentages and mean fluorescence intensity (MFI) were lower in a group of 127 cases of aggressive B-cell lymphomas compared to a control group of benign reactive hyperplasia. We also observed significant variability in the surface expression of CD79b among lymphoma cases, with 18% showing predominantly intracellular positivity. There was a strong correlation between the surface expression of CD79b and clonal light chains. Notably, primary mediastinal B-cell lymphomas exhibited significantly lower surface CD79b expression compared to other lymphoma subtypes (median 0.8% IQR 0–48.5 vs. 80% IQR 24–97,p= 0.0005). Furthermore, patients over 60 years old and those with a higher Revised International Prognostic Index (R-IPI) had significantly higher CD79b expression, both of which are associated with a significant benefit from adding an anti-CD79b drug conjugate to first-line chemotherapy in diffuse large B-cell lymphomas.Conclusions:In conclusion, the quantitative flow cytometric analysis of CD79b surface expression in aggressive B-cell lymphomas provides clinically relevant information, highlighting its potential usefulness in guiding therapeutic decisions.
背景：CD79b是一种B细胞特异性抗原，对B细胞受体至关重要，被认为是侵袭性B细胞淋巴瘤治疗的关键靶点。 方法：虽然免疫组织化学研究显示CD79b在成熟B细胞来源的淋巴瘤中广泛表达，但流式细胞术能够精确测量并区分其表面与细胞内定位。 结果：在我们的比较分析中，我们发现127例侵袭性B细胞淋巴瘤的CD79b表达百分比和平均荧光强度（MFI）均低于良性反应性增生对照组。我们还观察到淋巴瘤病例中CD79b表面表达存在显著差异，其中18%的病例主要表现为细胞内阳性。CD79b的表面表达与克隆性轻链之间存在强相关性。值得注意的是，与其他淋巴瘤亚型相比，原发性纵隔B细胞淋巴瘤的CD79b表面表达显著降低（中位数0.8%，四分位距0–48.5 vs. 80%，四分位距24–97，p=0.0005）。此外，60岁以上患者及修订版国际预后指数（R-IPI）较高的患者CD79b表达显著更高，这两类患者在弥漫性大B细胞淋巴瘤的一线化疗中联合使用抗CD79b药物偶联物均显示出显著获益。 结论：总之，对侵袭性B细胞淋巴瘤中CD79b表面表达的定量流式细胞分析提供了临床相关信息，突显了其在指导治疗决策中的潜在应用价值。
肿瘤(癌症)患者之家